Japan· JP-2160006F2022
リザトリプタン安息香酸塩
A medicinal product containing リザトリプタン安息香酸塩, registered in Japan by オルガノン, on the national reimbursement list.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- リザトリプタン安息香酸塩
- Manufacturer
- オルガノン
- Country
- Japan (JP)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
リザトリプタン安息香酸塩 in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomMaxalt 10mg tabletsLexon (UK) Ltd
- SpainMAXALT 10 mg COMPRIMIDOSOrganon Salud S.L.
- CanadaACCEL-RIZATRIPTAN ODTACCEL PHARMA INC
- ItalyEMIRIZIANEURAXPHARM ITALY S.P.A.
- SwitzerlandMaxalt 10 mg, TablettenOrganon GmbH
- NetherlandsMaxalt 10 mg, tablettenN.V. Organon
- SwedenRizasmelt 10 mg Munsönderfallande tablettSTADA Arzneimittel AG
- FranceMAXALT 10 mg, compriméORGANON FRANCE
Authorised across Europe · EMA
The same active substance is authorised in 11 EEA countries. Names it is sold under:
- Germany · Rizatriptan Al, Rizatriptan Glenmark
- Denmark · Rizasmelt, Rizatriptan ”stada”
- Spain · Rizatriptán Flas Kern Pharma, Rizatriptán Max Viatris
- Finland · Rizastad, Rizatriptan Stada
- France · Rizatriptan Eg, Rizatriptan Viatris
- United Kingdom (Northern Ireland) · Rizatriptan Glenmark Pharmaceuticals Europe, Rizatriptan Macleods Pharma Uk
- Croatia · Emalt
- Italy · Rizatriptan Mylan Generics, Rizatriptan Sandoz
- Netherlands · Rizatriptan Sandoz, Rizatriptan Viatris
- Sweden · Rizasmelt, Rizatriptan Glenmark
- Slovakia · Rizatriptan Sandoz, Rizatriptan Viatris
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6a305e30-69e8-4bea-a1ef-b4e96a0c437d GET /v1/drugs/6a305e30-69e8-4bea-a1ef-b4e96a0c437d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "10mg1錠",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "2160006F2022",
"category": "内用薬",
"price_yen": 177.6,
"generic_name": "リザトリプタン安息香酸塩",
"product_name_jp": null,
"therapeutic_class": "2160",
"transitional_expiry": null
}See everything about リザトリプタン安息香酸塩.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.